MOLECULAR CANCER THERAPEUTICS

Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer

MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors

A Simple Three-dimensional Hydrogel Platform Enables Ex Vivo Cell Culture of Patient and PDX Tumors for Assaying Their Response to Clinically Relevant Therapies

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression

Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition

Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model

Ceramide–Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations

Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors

Morin Inhibits Proliferation and Induces Apoptosis by Modulating the miR-188-5p/PTEN/AKT Regulatory Pathway in CML Cells

Reduction of Muscle-Invasive Tumors by Photodynamic Therapy with Tetrahydroporphyrin-Tetratosylat in an Orthotopic Rat Bladder Cancer Model

GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression

Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity

Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics

The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors

Abstract B126: A small molecule inhibitor of the RNA m6A writer METTL3 inhibits the development of acute myeloid leukemia (AML) in vivo

Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer

Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma

Abstract B024: Clinical, genomic, and immune landscape of the receptor tyrosine kinase AXL in non-small cell lung cancer

Abstract A077: FIGHT-207: Phase 2 study of pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor (FGFR) gene alterations

Abstract B070: LOCUS database enables rapid query and targeted selection of preclinical tumor models based on cancer genomics and pharmacologic response

Abstract B016: CDK7 inhibition suppresses AR addicted Castration-Resistant Prostate Cancer through MED1 inactivation

Abstract B052: ATR inhibition potentiates ionizing radiation-induced innate immune response via sensing cytosolic RNAs

Abstract A080: Olaparib and the ATR inhibitor AZD6738 in relapsed, refractory cancer patients with homologous recombination (HR) repair mutations – OLAPCO

Abstract A038: Assessment of angiogenesis markers in advanced cervical carcinoma patients that received chemoradiation therapy plus/minus neoadjuvant chemotherapy

Abstract A120: Adaptive mutability of colorectal cancers in response to targeted therapies

Abstract LB-C11: Targeting metastatic prostate cancer with a multi-functional therapy approach

Abstract C067: Mechanistic study of the superior anti-cancer properties of a first-in-class small molecule targeting PCNA

Abstract A135: Discovery of BGS1954, a covalent small molecule ligand of FABP5 using IMTACTM platform

Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

Abstract B137: Visualization and quantification of tumor-immune cell interactions in 3D cultures

Abstract C064: The investigational peptide drug ALRN-6924, a dual inhibitor of MDMX and MDM2, is an effective myelopreservation agent

Abstract LB-C05: The autism and schizophrenia-associated CYFIP1 protein is required for pancreatic tumor growth and presents a potential therapeutic target

Abstract C059: Inhibition of thymidylate synthase by the ProTide NUC-3373: in vitro analysis and clinical validation

Abstract CN09-01: Lessons learnt in clinic from resistance to first generation molecular targeted therapies in solid cancers

Abstract LB-A10: ORIC-101 overcomes glucocorticoid-driven resistance to enzalutamide in castration-resistant prostate cancer

Abstract KN01: Dissecting antitumor immune response in ovarian cancer

Abstract A012: Mammary fat pad injections: An alternative implantation method for syngeneic tumor models

Abstract A034: The use of biomarkers and ctDNA in a phase 1 trial of ARQ 751

Abstract LB-C07: Preclinical evaluation of MCLA-129: A bispecific antibody targeting c-MET and EGFR

Abstract C117: Development of autologous tumor: TIL coculture from patient-derived samples for in vitro preclinical immuno-oncology studies

Abstract C132: Fusobacterium nucleatum in colorectal carcinoma and expression of multiple immune checkpoint molecules on T cells

Abstract B009: The histone deacetylase inhibitor pracinostat and its metabolite SB991 are active as single agents and in combination with 5-azacitidine in acute myeloid leukemia cells

Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance

Abstract A099: Acoustic Cluster Therapy enhances the efficacy of chemotherapeutic regimens in patient-derived xenograft mouse models for pancreatic ductal adenocarcinoma

Abstract LB-B17: Uncovering novel cancer therapeutics using the Exoneural Medicines Platform: The role of innervation in cancer

Abstract C120: The tumor suppressor role of STXBP6 in triple negative breast cancer

Abstract A001: Colorectal cancer cell-derived exosomes containing miR-183-5p regulate angiogenesis via FOXO1